Effects of Heparin Oligosaccharides with High Affinity for Antithrombin III in Experimental Venous Thrombosis

Summary

The in vitro and in vivo characteristics of two oligosaccharide heparin fragments have been compared to those of unfractionated mucosal heparin. A decasaccharide fragment had essentially no activity by APTT or calcium thrombin time assays in vitro, but possessed very high specific activity by anti-Factor Xa assays. When injected into rabbits at doses of up to 80 ¼g/kg, this fragment was relatively ineffective in impairing stasis thrombosis despite producing high blood levels by anti-Xa assays. A 16-18 monosaccharide fragment had even higher specific activity (almost 2000 iu/mg) by chromogenic substrate anti-Xa assay, with minimal activity by APTT. When injected in vivo, this fragment gave low blood levels by APTT, very high anti-Xa levels, and was more effective in preventing thrombosis than the decasaccharide fragment. However, in comparison with unfractionated heparin, the 16-18 monosaccharide fragment was only partially effective in preventing thrombosis, despite producing much higher blood levels by anti-Xa assays.

It is concluded that the high-affinity binding of a heparin fragment to antithrombin III does not by itself impair venous thrombogenesis, and that the anti-Factor Xa activity of heparin is only a partial expression of its therapeutic potential.

Key words

Heparin - Oligosaccharides - Venous thrombosis

• References

• 1 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 2 Lane DA, MacGregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271
• 3 Laurent TC, Tengblad A, Thunberg L, Höök M, Lindahl U. The molecular weight-dependence of the anti-coagulant activity of heparin. Biochem J 1978; 175: 691-701
• 4 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
• 5 Lane DA, MacGregor IR, Van Ross M, Cella G, Kakkar VV. Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins to man. Thromb Res 1979; 16: 651-662
• 6 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
• 7 Thomas DP. Heparin in the prophylaxis and treatment of venous thrombosis. Semin Haematol 1978; 15: 1-17
• 8 Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA 1979; 76: 3198-3202
• 9 Thunberg L, Bäckström G, Grundberg H, Riesenfeld J, Lindahl U. The molecular size of the antithrombin-binding sequence in heparin. FEBS Lett 1980; 117: 203-206
• 10 Holmer E, Lindahl U, Bäckström G, Thunberg L, Sandberg H, Söderström G, Andersson L-O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-869
• 11 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
• 12 Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin binding sequence in heparin. Carbohydr Res. 1982 (in press)
• 13 Meyer B, Thunberg L, Lindahl U, Larm O, Leder IG. The antithrombin binding sequence of heparin studied by n.m.r. spectroscopy. Carbohydr Res 1981; 88: C1-C4
• 14 Lindahl U, Bäckström G, Thunberg L, Leder IG. Evidence for a 3-0-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980; 6551-6555
• 15 Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring plasma inhibitor to activated Factor X. J Biol Chem 1971; 246: 3703-3711
• 16 Kakkar VV, Field ES, Nicolaides AN, Flute PT, Wessler S, Yin ET. Low doses of heparin in prevention of deep-vein thrombosis. Lancet 1971; 1: 669-671
• 17 Wessler S. Small doses of heparin and a new concept of hypercoagulability. Thrombos Diathes Haemorrh 1974; 33: 81-86
• 18 Ockelford PA, Carter CJ, Hirsh J. The lack of relationship between anti-Xa activity and antithrombotic activity of low molecular weight heparin. Thromb Haemostas 1981; 46: 116 (Abstr)
• 19 Thunberg L, Lindahl U, Tengblad A, Laurent TC, Jackson CM. On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J 1979; 181: 241-243
• 20 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor XIIa und kallikrein by antithrombin. Biochem J 1981; 193: 395-400
• 21 Ooosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981; 78: 829-833
• 22 Glimelius B, Busch C, Höök M. Binding of heparin on the surfaces of cultured human endothelial cells. Thromb Res 1978; 12: 773-782
• 23 Lindahl U, Höök M. Glycosaminoglycans and their binding to biological macromolecules. Ann Rev Biochem 1978; 47: 385-417